Tambocor Related Published Studies
Well-designed clinical trials related to Tambocor (Flecainide)
Flecainide for the treatment of chronic neuropathic pain: a Phase II trial. [2007.12]
Dose-response effect of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephonic electrocardiography: a multicenter, placebo-controlled, double-blind trial. [2007.03]
Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol. [2005.10]
Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation. [2004.12]
Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. [2004.08]
Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation. [2004.03]
Pharmacodynamic equivalence of two flecainide acetate formulations in patients with paroxysmal atrial fibrillation by QRS analysis of ambulatory electrocardiogram. [2003.05]
Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. [2002.08]
Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. [2001.05]
[Effectiveness and side effects of the treatment with propafenone and flecainide for recent-onset atrial fibrillation] [2001.01]
Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. [2000.11.01]
Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. [2000.07]
Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. [1998.06.15]
[Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias] [1997.02]
A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The Flecainide Multicenter Investigators Group. [1996.01.25]
Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. [1996.01.25]
Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. [1996.01.25]
Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. [1996.01.25]
Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. [1995.12]
Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. [1995.12]
[Propafenone and flecainide in the therapy of ventricular arrhythmias] [1995.10]
Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study. [1995.05]
Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. [1995.04.01]
Effects of flecainide on exercise hemodynamics and electrocardiography in patients without structural heart disease. [1995.03]
[A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation] [1995.01]
Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). [1994.12]
Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). [1994.02]
Partial reversal by exercise of protective effect in atrial fibrillation inducibility in patients with an accessory atrioventricular connection: comparison between flecainide and propafenone. [1994.02]
Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. [1994]
Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). [1993.11.24]
Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. [1993.08]
Oral flecainide, sotalol, and verapamil for the termination of paroxysmal supraventricular tachycardia. [1993.07]
Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function. [1993.04]
A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. [1992.09]
Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. [1992.08.20]
Efficacy of flecainide for the reversion of acute onset atrial fibrillation. [1992.08.20]
Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. [1992.08.20]
Washout of long-term treatment with flecainide and propafenone in patients with complex ventricular arrhythmias and cardiac disease. Antiarrhythmic Drug Evaluation Group. [1992.08]
Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. [1992.07.01]
The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. [1992]
Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. [1991.12.15]
A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. [1991.11]
Prevention of arrhythmias after noncardiac thoracic operations: flecainide versus digoxin. [1991.06]
Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. [1991.04.01]
Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation. [1991.04]
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. [1991.03.21]
Trial of flecainide acetate in the management of tinnitus. [1991.02]
Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. [1991.01.15]
Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. [1991.01]
A double-blind crossover comparison of flecainide and slow-release mexiletine in the treatment of stable premature ventricular complexes. [1991]
Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. [1990.09.14]
[The efficacy of oral treatment with flecainide for paroxysmal atrial fibrillation: correlation with plasma concentration] [1990.06]
Absorption kinetics of oral and rectal flecainide in healthy subjects. [1990]
Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. [1989.12.01]
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. [1989.12]
Prevention of arrhythmias by flecainide after noncardiac thoracic surgery. [1989.08]
Encainide and flecainide: are they interchangeable? [1989.06]
Efficacy of flecainide acetate for atrial arrhythmias following coronary artery bypass grafting. [1989.05.01]
Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. [1989.03.15]
Flecainide and cardiac dysrhythmias during dental extraction under anaesthesia. [1989.01]
Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. [1989.01]
Flecainide compared with a combination of digoxin and disopyramide for acute atrial arrhythmias after cardiopulmonary bypass. [1988.12]
Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. [1988.06]
[Comparative multicenter clinical study of flecainide and amiodarone in the treatment of ventricular arrhythmias associated with chronic Chagas cardiopathy] [1987.07]
Well-designed clinical trials possibly related to Tambocor (Flecainide)
Physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey. [2010.03]
Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias. [2009.10]
A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. [2006.12.05]
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. [2006.10.01]
Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: evidence from randomized clinical trials. [2005.05]
VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). [2003.08]
Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. [2003.01]
An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. [2002.06]
Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. [2001.09]
Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. [2001.02]
Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. [1998.11]
Mechanism of antiarrhythmic effects of class Ic drugs in paroxysmal atrial fibrillation in man. [1998]
[Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence] [1997.02]
Continuation of antiarrhythmic drugs, or arrhythmia surgery after multiple drug failures. A randomized trial in the treatment of postinfarction ventricular tachycardia. [1996.04]
Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST). [1996.03]
The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice. [1996.01]
Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. [1995.07]
Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. [1995.05]
Association between ease of suppression of ventricular arrhythmia and survival. [1995.01.01]
Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. [1994.11]
Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy. [1994.03.01]
[The use of digitalis glycosides in atrial fibrillation] [1994]
Psychosocial predictors of mortality in the Cardiac Arrhythmia Suppression Trial-1 (CAST-1). [1993.02.01]
Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators. [1992.07]
The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. [1992.04]
The McCollough effect as a measure of central cholinergic activity in man. [1992]
Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. [1991.11.15]
Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. [1991.10.01]
Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. [1991.07]
Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy. [1991.07]
The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. [1990.12]
Clinical aspects of trial design: what can we expect from the cardiac arrhythmia suppression trial? [1990.06]
Recasting the approach to the treatment of potentially malignant ventricular arrhythmias after the CAST study. [1990.06]
Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias. [1990.02.20]
Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment. [1990.02.20]
The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. [1990.01.16]
Combined anti-arrhythmic therapy with class 1 and class 3 drugs. [1989.08]
|
